Thermo Fisher to scale its trading with its price offering of the Euro-denominated Notes

Announcement

Thermo Fisher Scientific Inc. declared that it has listed the pricing of the €2.1 billion offerings, estimated principal amount of the euro-denominated senior notes. This will be released by Thermo Fisher Scientific (Finance I) B.V., it’s a financial indirect wholly owned finance subsidiary body that looks after the trading business of Thermo Fisher. As per the subsidiary norms, around €1,000,000,000 accumulated principal amount of its floating rate senior notes due 2027 will be fixed at the issued price of 100.000% of their principal amount.

The second norm states that €1 1000,000,000 accumulated principal amount of its 3.628 per cent senior notes due 2035, which are the fixed rate notes considered with the floating rate notes, will be at the issue price of 100.000% of their principal amount.

Offering’s understanding

The offerings are predicted to get near the closing on or about 1st December 2025, entitled to the satisfaction of customary closing conditions. The notes through this offering will be precisely unconditionally promised by Thermo Fisher. The fixed-rate notes will be liable to pay interest every year, whereas the floating-rate notes will pay interest every quarter.

The Thermo Fisher plans to use the net proceeds from the sale of the notes for basic corporate purposes that might include repayment, refinancing of debt, capital expenditures, working capital or repurchase of its outstanding equity securities and acquisition of businesses or companies. Or else it might temporarily invest the net proceeds under the liquid investments for a short period until the main purpose arrives.

For these offerings, the joint book-running managers are BNP PARIBAS, Morgan Stanley & Co. International plc, Barclays Bank PLC and HSBC Continental Europe. Further, the offering is titled pursuant to an official registration statement for confirmation on Form S-3ASR (File No. 333-285159) punched in filed by Thermo Fisher with the U.S Securities and Exchange Commission (SEC) on 24th February 2025. It will be considered only by means of an accompanying prospectus and prospectus supplement.

The issuer's free writing prospectus and a preliminary prospectus supplement have also been filed along with the prospectus supplement regarding the Offering poised with the SEC. The prospective investors have been told to read the preliminary prospectus supplement, accompanying prospectus and the issuer's free writing prospectus that will be a part of the documentation and registration statement that the company has filed with the SEC. This will also give a close insight into Thermo Fisher and its offerings.